AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25109511 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Stablon®)
Number of subjects: 40
Study 22806076 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (0.3 g/kg)
Number of subjects: 17
Study 22806076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 g/kg cornstarch maltodextrin + 0.1 g/kg sucrose)
Number of subjects: 17
Study 19028462 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Stroop task (dual-task condition)
Number of subjects: 24
Study 19028462 — intervention group
Group type: COMPARATOR
Intervention: Single-task performance (congruent vs. incongruent)
Number of subjects: 24
Study 17523902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% ropivacaine instilled into the renal puncture site, nephrostomy tract, and skin
Number of subjects: 34
Study 17523902 — intervention group
Group type: COMPARATOR
Intervention: Saline instilled into the renal puncture site, nephrostomy tract, and skin (Control)
Number of subjects: 34
Study 15358872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day workshop
Number of subjects: 0
Study 15358872 — intervention group
Group type: EXPERIMENTAL
Intervention: six individual sessions
Number of subjects: 0
Study 11394466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional stick electrode welding process (SMAW)
Number of subjects: 7
Study 11394466 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire welding process (FCAW)
Number of subjects: 7
Study 11394466 — intervention group
Group type: COMPARATOR
Intervention: Both SMAW and FCAW
Number of subjects: 7
Study 9700034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 750 microg/day
Number of subjects: 21
Study 9700034 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1500 microg/day
Number of subjects: 21
Study 9700034 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 21
Study 9700034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7862853 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg at the beginning and 50 mg maintenance dose half-way through the session
Number of subjects: 30
Study 2144705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg twice daily for 3 weeks, then 20 mg twice daily for 3 weeks
Number of subjects: 37
Study 2144705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily for 3 weeks, then 100 mg once daily for 3 weeks
Number of subjects: 37
Study 2144705 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37
Study 2144705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 37
Study 380608 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (2.0 mg oral, 1.0 mg i.m.)
Number of subjects: 0
Study 380608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (1.0 mg oral, 0.25-0.5 mg i.m.)
Number of subjects: 0
Study 380608 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (0.2 mg i.m.)
Number of subjects: 0
Study 380608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31045427 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered condition (phone or in-person)
Number of subjects: 277
Study 31045427 — intervention group
Group type: COMPARATOR
Intervention: Self-administered condition (via the Assessment Center website)
Number of subjects: 277
Study 27808596 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality based treadmill training (n=14)
Number of subjects: 25
Study 27808596 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (control group, n=11)
Number of subjects: 25
Study 25645169 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavior therapy)
Number of subjects: 72
Study 25645169 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study 25530242 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterschool intervention promoting water intake
Number of subjects: 20
Study 25530242 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation factors influencing water intake
Number of subjects: 20
Study 22329753 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incentive ($5)
Number of subjects: 0
Study 22329753 — intervention group
Group type: EXPERIMENTAL
Intervention: Large incentive ($50)
Number of subjects: 0
Study 22329753 — intervention group
Group type: EXPERIMENTAL
Intervention: Partisans with strong belief in their predictions
Number of subjects: 0
Study 22329753 — intervention group
Group type: COMPARATOR
Intervention: Neutrals
Number of subjects: 0
Study 19458926 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone 300 mg/day
Number of subjects: 80
Study 19458926 — intervention group
Group type: COMPARATOR
Intervention: Baclofen 60 mg/day
Number of subjects: 80
Study 18085137 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAO's 'five needling methods'
Number of subjects: 210
Study 18085137 — intervention group
Group type: COMPARATOR
Intervention: Routine needling method
Number of subjects: 210
Study 15366324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 0
Study 15366324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.25, 0.5, and 1 mg x kg(‐1))
Number of subjects: 0
Study 15366324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11336107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g, intravenous)
Number of subjects: 10
Study 9537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187
Study 9537847 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 187
Study 8033487 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 0
Study 8033487 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 0
Study 8033487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2898319 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750 mg or 1000 mg once-a-day)
Number of subjects: 404
Study 2898319 — intervention group
Group type: COMPARATOR
Intervention: Standard marketed naproxen (375 mg or 500 mg twice-a-day)
Number of subjects: 404
Study 2898319 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750 mg or 1000 mg once-a-day) during open-label phase
Number of subjects: 404
Study 31081951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-thrusting group (n=8)
Number of subjects: 11
Study 31081951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thrusting group (n=3)
Number of subjects: 11
Study 31081951 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (n=8)
Number of subjects: 11
Study 28595089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 62
Study 28595089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25636011 — intervention group
Group type: EXPERIMENTAL
Intervention: HalfLytely© 1 L × 2 doses and bisacodyl 5 mg delayed release tablets × 2 tablets (Protocol 1)
Number of subjects: 209
Study 25636011 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX® 5 tablespoons × 2 doses and bisacodyl 5 mg tablets × 2 tablets (Protocol 2)
Number of subjects: 209
Study 25636011 — intervention group
Group type: EXPERIMENTAL
Intervention: MoviPrep 1 L × 2 doses (Protocol 3)
Number of subjects: 209
Study 23486859 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐16/18 vaccine
Number of subjects: 334
Study 23486859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Al(OH)3 control)
Number of subjects: 334
Study 21244304 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 21244304 — intervention group
Group type: COMPARATOR
Intervention: Various dystonia medications (anticholinergic agents, baclofen, clonazepam, tetrabenazine, clozapine)
Number of subjects: 0
Study 19266393 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch
Number of subjects: 10
Study 19266393 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 10
Study 18632034 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet on diabetes and LRTIs and UTIs
Number of subjects: 200
Study 18632034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 200
Study 14992906 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-filtered blood cardioplegia/reperfusion
Number of subjects: 160
Study 14992906 — intervention group
Group type: COMPARATOR
Intervention: Standard blood cardioplegia/reperfusion (control group)
Number of subjects: 160
Study 11486568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 30
Study 11486568 — intervention group
Group type: COMPARATOR
Intervention: No cold pressor test (control)
Number of subjects: 30
Study 9014973 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 3526
Study 9014973 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 3526
Study 9014973 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG within the first 4 days of randomization
Number of subjects: 3526
Study 9014973 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 3526
Study 7681050 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose rate brachytherapy (1000 cGy at 5 mm depth for three fractions)
Number of subjects: 318
Study 7681050 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (1000 cGy at 10 mm depth for three fractions)
Number of subjects: 318
Study 7681050 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Number of subjects: 318
Study 3536050 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 42
Study 3536050 — intervention group
Group type: COMPARATOR
Intervention: Control (no thymostimulin)
Number of subjects: 42
Study 31095973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 38
Study 31095973 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (Control)
Number of subjects: 38
Study 28851233 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 87
Study 28851233 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Shuttle Walk Test (ESWT)
Number of subjects: 87
Study 28851233 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant characteristics (age, lung function, nadir SpO2, end-test dyspnoea)
Number of subjects: 87
Study 27189687 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Nights/Better Days intervention (five-session manual and weekly telephone coach support)
Number of subjects: 61
Study 27189687 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61
Study 27189687 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy results
Number of subjects: 61
Study 27189687 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent satisfaction ratings
Number of subjects: 61
Study 25590463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) with a focus on cognitive restructuring
Number of subjects: 0
Study 25590463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) focusing on Stress Management
Number of subjects: 0
Study 23001395 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute NaHCO3 loading (AL)
Number of subjects: 8
Study 23001395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial NaHCO3 loading (SL)
Number of subjects: 8
Study 23001395 — intervention group
Group type: COMPARATOR
Intervention: Placebo loading condition (P)
Number of subjects: 8
Study 20096466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacotherapy and adjunctive psychosocial treatment based on a cognitive‐behavioral model)
Number of subjects: 20
Study 20096466 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (standard drug treatment)
Number of subjects: 20
Study 17497570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT)
Number of subjects: 17
Study 17497570 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 17
Study 17497570 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 17
Study 16263860 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment over 12 to 16 weeks
Number of subjects: 88
Study 12411067 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with an iodine concentration of 25 mg/kg (Group A)
Number of subjects: 0
Study 12411067 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt purchased from the market (Group B)
Number of subjects: 0
Study 12411067 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt purchased from the market + iodized oil capsules containing 400 mg iodine (Group C)
Number of subjects: 0
Study 12411067 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 10219530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetmin Retard
Number of subjects: 12
Study 10219530 — intervention group
Group type: COMPARATOR
Intervention: Glucophage Retard
Number of subjects: 12
Study 7666878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 1633
Study 7666878 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic surgeons
Number of subjects: 1633
Study 7666878 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care practitioners
Number of subjects: 1633
Study 7666878 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO providers
Number of subjects: 1633
Study 7666878 — intervention group
Group type: COMPARATOR
Intervention: All practitioners
Number of subjects: 1633
Study 1982830 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) self‐administered R‐EPO (starting dose 92 +/‐ 35 U/kg/week) two times a week
Number of subjects: 16
Study 1982830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) R‐EPO (170 +/‐ 42 U/kg/week) thrice weekly
Number of subjects: 16
Study 343967 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 40
Study 343967 — intervention group
Group type: COMPARATOR
Intervention: Oral meperidine 75 mg
Number of subjects: 40
Study 343967 — intervention group
Group type: COMPARATOR
Intervention: Oral propoxyphene 65 mg
Number of subjects: 40
Study 343967 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 40
Study 30732471 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive anti-radiation shield under the angiographic table (group 2)
Number of subjects: 157
Study 30732471 — intervention group
Group type: COMPARATOR
Intervention: Standard arrangement (group 1)
Number of subjects: 157
Study 30732471 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different under-the-table shields (small curtain and drape)
Number of subjects: 157
Study 27317032 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (100 mg rectally)
Number of subjects: 272
Study 27317032 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1 g intravenously)
Number of subjects: 272
Study 25611308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% cis‐urocanic acid (cis‐UCA) eye drops
Number of subjects: 37
Study 25611308 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% cis‐urocanic acid (cis‐UCA) eye drops
Number of subjects: 37
Study 25611308 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 37
Study 25611308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐UCA concentrations in plasma
Number of subjects: 37
Study 25611308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐UCA excretion in urine
Number of subjects: 37
Study 24218460 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 IU/kg as dl‐α‐tocopheryl acetate)
Number of subjects: 93
Study 24218460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 93
Study 21088862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LEDT (69 LEDs with wavelengths 660/850 nm, 10/30 mW of output power, 30 s of irradiation time per point, total of 41.7 J irradiated per point)
Number of subjects: 6
Study 21088862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion Therapy (CWIT) (5°C of temperature [SD ±1°])
Number of subjects: 6
Study 21088862 — intervention group
Group type: COMPARATOR
Intervention: Placebo LEDT
Number of subjects: 6
Study 19372330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 15
Study 19372330 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 15
Study 19372330 — intervention group
Group type: EXPERIMENTAL
Intervention: New combined EEG/AEP indicator
Number of subjects: 15
Study 19372330 — intervention group
Group type: COMPARATOR
Intervention: Former 'detector of consciousness'
Number of subjects: 15
Study 16394188 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic versions of standard scales for assessing computer attitudes
Number of subjects: 443
Study 16394188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, years of teaching experience, computer use, computer experience
Number of subjects: 443
Study 14618332 — intervention group
Group type: EXPERIMENTAL
Intervention: Senegalese sprinters (S)
Number of subjects: 28
Study 11783762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bic/Lac (25 mmol/L bicarbonate/15 mmol/L lactate)
Number of subjects: 31
Study 11783762 — intervention group
Group type: COMPARATOR
Intervention: Lac (35 mmol/L lactate)
Number of subjects: 31
Study 9224307 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 443
Study 9224307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoglucid
Number of subjects: 443
Study 9224307 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 443
Study 9224307 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 443
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH alone (group I)
Number of subjects: 50
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH with buserelin intranasal spray (4 x 150 micrograms per day) in a short protocol (group II)
Number of subjects: 50
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH with buserelin in a long protocol (group III)
Number of subjects: 50
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH with triptorelin (3.75 mg i.m. in a long protocol) (group IV)
Number of subjects: 50
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH with triptorelin (200 micrograms daily s.c. injections) (group V)
Number of subjects: 50
Study 7962377 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 50
Study 7962377 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 3315606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 0
Study 3315606 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 0
Study 31100091 — intervention group
Group type: EXPERIMENTAL
Intervention: First team players
Number of subjects: 119
Study 31100091 — intervention group
Group type: COMPARATOR
Intervention: Reserves
Number of subjects: 119
Study 29286560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and motivation-based intervention (n=33)
Number of subjects: 73
Study 29286560 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=40)
Number of subjects: 73
Study 28043418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime (PAM) treatment guided by APACHE II scores and BuChE activity
Number of subjects: 46
Study 28043418 — intervention group
Group type: COMPARATOR
Intervention: WHO's recommended PAM regimen
Number of subjects: 46
Study 24639094 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-RT (20-30% 1-RM, knee extension and leg press)
Number of subjects: 0
Study 24639094 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 0
Study 21818576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 140
Study 21818576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 19914662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (15% kcal), high fiber, soy protein supplemented diet
Number of subjects: 18
Study 19914662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (15% kcal)
Number of subjects: 18
Study 19914662 — intervention group
Group type: COMPARATOR
Intervention: Western diet (40% kcal fat)
Number of subjects: 18
Study 18805335 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment modified based on measurements of fraction of exhaled NO
Number of subjects: 546
Study 18805335 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment based on NAEPP guidelines (Control)
Number of subjects: 546
Study 15224298 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroinfusion-supported stenting (n = 23)
Number of subjects: 44
Study 15224298 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery (n = 21)
Number of subjects: 44
Study 15224298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 11346806 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer (lead chelator), administered orally in up to three 26-day courses
Number of subjects: 780
Study 11346806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 11346806 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780
Study 9812581 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with carbohydrate as major composition
Number of subjects: 30
Study 9812581 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with higher lipid and protein composition
Number of subjects: 30
Study 9812581 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with reasonable calorie allocation
Number of subjects: 30